Market Access Multiple myeloma drug Blenrep backed for wider NHS use PharmaphorumThe revitalisation of GSK's Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely.Market AccessOncologyRead full story pharminent April 17, 2026 (Last updated: April 17, 2026) Pharmaphorum The revitalisation of GSK’s Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely. Market AccessOncologyRead full story Post navigation Previous: Daiichi Sankyo and Interna partner for MNM-targeted delivery solutionsNext: Replimune cries foul on regulatory flexibility. But many Americans want a stricter FDA Related Stories Market Access Deal finally unlocks NHS access to ITF’s Duchenne drug pharminent May 11, 2026 Market Access Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point pharminent May 5, 2026 Market Access Where Gross-to-net Pressure Actually Lives After Launch pharminent May 1, 2026
